pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Undisclosed · news · pharmadog
← back to Undisclosed
News mentioning Undisclosed
36
stories
14h
Lilly pens deal with Gateway Labs alumni Amplitude for RNA vaccine platform for infectious disease
fiercebiotech
1d
Kolon TissueGene cuts 37 US staffers after Phase 3 fail
biospace
2d
LEO adds to dermatology portfolio with $435M deal for late-stage rare disease drug
biospace
3d
Slate, Fulcrum to combine in reverse merger
biopharma dive
3d
J&J hands lymphoma bispecific CAR T back to AbelZeta
biospace
3d
Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague
fiercebiotech
6d
After 2 undisclosed gene therapy deaths, can China’s alternative regulatory path still be trusted?
fiercebiotech
7d
Zealand sells milestone, royalty rights to rare blood cancer asset for up to $100M
biospace
8d
Sentynl bets up to $475M in licensing deal for Mereo’s rare lung disease asset
biospace
9d
Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs
biopharma dive
9d
After billions in deals, Insilico CEO promises: ‘You haven't seen anything yet’
biospace
9d
Epicrispr, Infinimmune snag combined $165M in VC cash
biospace
9d
Zydus’ Sentynl pens $475M deal for Mereo’s phase 3-ready rare genetic lung disease drug
fiercebiotech
10d
AstraZeneca partners with CSPC to build Chinese biologics manufacturing plant
biospace
10d
Jazz pays $820M to buy Actio, adding clinical-stage asset to orchestra of epilepsy therapies
fiercebiotech
15d
STAT+: Exemption of rare disease therapies in drug-pricing pilots would wipe out huge savings, analysis finds
stat
15d
5 NextGen winners who went public this year (and which ones are hiring)
biospace
16d
Sanofi-backed Expedition uses $115M series B to advance COPD drug on phase 2 journey
fiercebiotech
23d
Boston Scientific unveils major restructuring, plots job cuts amid savings drive
fiercebiotech
Jul 20, 26
FDA’s radical transparency policy for rejections runs into legal uncertainty
biospace
Jul 17, 26
This Week at FDA: FDA staff raise concerns about peptide conflicts, top Democrat wants DOGE investigation, and more
raps
Jun 26, 26
FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services
biopharma dive
Jun 18, 26
Biogen adds more immune drugs in $1B buyout of secretive startup RayThera
biopharma dive
Jun 3, 26
Lilly, Ascidian link up in RNA exon editing pact
biopharma dive
May 1, 26
STAT+: Pharmalittle: We’re reading about obesity drugs and a compounding list, an AstraZeneca setback, and more
stat
Apr 30, 26
STAT+: Pharmalittle: We’re reading about a Supreme Court hearing on ‘skinny labels,’ AstraZeneca U.K. expansion, and more
stat
Apr 29, 26
STAT+: Supreme Court justices appear to signal ‘skinny labeling’ can survive
stat
Apr 29, 26
FDA tests out ‘real-time’ clinical trials; AbbVie closes in on a KRAS biotech
biopharma dive
Apr 29, 26
STAT+: Pharmalittle: We’re reading about the FDA speeding up trials, a Supreme Court hearing on ‘skinny labels,’ and more
stat
Apr 29, 26
Food safety experts warn of USDA brain drain
stat
← prev
page 1 of 2
next →
